1. Bispecific antibodies targeting PD1 and VEGF demonstrate potential in treating non-small cell lung cancer (NSCLC), with Summit Therapeutics' Ivonescimab showing superior efficacy to Pembrolizumab in a Phase III trial; 2. Early-stage data from competitors like Instil Bio indicate promising therapeutic outcomes; 3. Pfizer (high dividend yield) and Instil Bio (undervalued) are highlighted as investment opportunities, though risks remain due to limited clinical data and the developmental stage of bispecific antibodies.